Concepedia

Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial

Dick de Zeeuw, Rajiv Agarwal, Michael Amdahl, Paul Audhya, Daniel W. Coyne, Τushar Garimella, Hans‐Henrik Parving, Yili Pritchett, Giuseppe Remuzzi, Eberhard Ritz,

The Lancet · 2010 · 690 citations · 32 references

DOI

Concepts

References

32

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>

Aram V. Chobanian · JAMA · 2003 · 25.6K citations

, , +17

Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events

The ONTARGET Investigators · New England Journal of Medicine · 2008 · 3.5K citations · Full text

, , +12

1,25-Dihydroxyvitamin D3 is a negative endocrine regulator of the renin-angiotensin system

Yan Chun Li, Juan Kong, Minjie Wei et al. · Journal of Clinical Investigation · 2002 · 1.8K citations · Full text

, , +15

1,25-Dihydroxyvitamin D3 is a negative endocrine regulator of the renin-angiotensin system

Yan Chun Li, Juan Kong, Minjie Wei et al. · Journal of Clinical Investigation · 2002 · 1.6K citations · Full text

, , +15

Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial

Johannes F.E. Mann, Roland E. Schmieder, Matthew McQueen et al. · The Lancet · 2008 · 1.6K citations

, , +12